3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Medullary
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
telotristat ethyl
3
lutetium Lu 177 dotatate
3
3-Iodobenzylguanidine
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vandetanib
1
gallium Ga 68 dotatate
1
Tretinoin
1
Temozolomide
1
Isotretinoin
1
Introns
1
Everolimus
1
Capecitabine
1
177Lu-octreotate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neuroendocrine Tumors
×
vandetanib
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn